San Diego-based Travere Therapeutics (Nasdaq: TVTX) announced an upsized convertible debt financing on May 6, 2026, structured primarily to retire a portion of its existing 2029 convertible note obligations and extend its debt maturity profile. The Travere convertible notes offering priced at USD 475 million in aggregate principal, up from the initially marketed USD 400 million, with net proceeds estimated at approximately USD 460 million after underwriter discounts and expenses. If underwriters exercise their 30-day over-allotment option in full — covering up to an additional USD 50 million — net proceeds would reach approximately USD 508.5 million.
The 2032 notes carry a 0.50% coupon and mature on May 15, 2032, with an initial conversion price of approximately USD 64.90 per share. Travere may settle conversions in cash, stock, or a combination. The notes become redeemable from May 2029, subject to share price conditions. The company plans to use approximately USD 350.9 million of proceeds to repurchase a portion of its existing 2029 convertible notes, with the remainder allocated to general corporate purposes.
Company overview and pipeline
Travere Therapeutics is a San Diego-based rare disease biopharmaceutical company focused on rare kidney and metabolic conditions. Its lead commercial asset is Filspari (sparsentan), a dual endothelin and angiotensin receptor antagonist approved for the treatment of IgA nephropathy. The fund raise follows the April approval of Filspari for a second indication of focal segmental glomerulosclerosis (FSGS) without nephrotic syndrome.